Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	AZD-6482	1	72	sigmoid	sigmoid	HCC38 AZD6482 0 1 72	8	1.732	Inf	0.862	0.0239	1.4	0.804	1.03	0.909	0.000761	NA	Inf	0.883	0.98	1.34	0.837	1.03	0.904	0.000873	NA
HCC38	AZD-6482	2	72	sigmoid	sigmoid	HCC38 AZD6482 0 2 72	8	2.132	Inf	0.898	0.0351	4.71	0.773	0.497	0.824	0.0055	NA	Inf	0.894	0.963	4.7	0.765	0.492	0.82	0.00588	NA
HCC38	AZD-6482	3	72	sigmoid	sigmoid	HCC38 AZD6482 0 3 72	8	1.420	Inf	0.821	0.0615	0.324	0.826	5.0	0.849	0.00342	NA	Inf	0.875	0.957	0.323	0.879	5.0	0.846	0.00367	NA
HCC38	AZD8055	1	72	sigmoid	sigmoid	HCC38 AZD8055 0 1 72	8	1.773	0.052	0.151	0.479	0.0381	0.136	1.02	0.992	4.28e-07	NA	0.116	0.375	0.633	0.0313	0.363	0.987	0.993	3.89e-07	NA
HCC38	AZD8055	2	72	sigmoid	sigmoid	HCC38 AZD8055 0 2 72	8	2.128	0.0616	0.16	0.467	0.045	0.124	0.912	0.993	3.13e-07	NA	0.0875	0.314	0.594	0.0332	0.284	0.869	0.991	6.5e-07	NA
HCC38	AZD8055	3	72	sigmoid	sigmoid	HCC38 AZD8055 0 3 72	8	1.417	0.0464	0.0327	0.53	0.0463	0.000983	1.04	0.997	4.27e-08	NA	0.157	0.392	0.658	0.041	0.372	1.02	0.996	5.78e-08	NA
HCC38	Buparlisib	1	72	sigmoid	sigmoid	HCC38 buparlisib 0 1 72	8	1.738	0.912	-0.226	0.194	1.46	-0.57	1.62	0.999	9.48e-10	NA	1.2	0.192	0.858	1.12	0.0495	1.66	0.998	4.36e-09	NA
HCC38	Buparlisib	2	72	sigmoid	sigmoid	HCC38 buparlisib 0 2 72	8	2.142	0.876	-0.185	0.172	1.24	-0.413	1.74	0.996	5.03e-08	NA	0.959	0.146	0.861	0.893	0.0606	1.8	0.992	4.3e-07	NA
HCC38	Buparlisib	3	72	sigmoid	sigmoid	HCC38 buparlisib 0 3 72	8	1.431	0.674	-0.377	0.272	1.67	-1.0	1.21	0.991	6.94e-07	NA	1.11	0.188	0.824	1.11	0.0	1.32	0.987	2.46e-06	NA
HCC38	BX-912	1	72	sigmoid	sigmoid	HCC38 BX-912 0 1 72	8	1.760	0.529	-0.322	0.274	0.591	-0.322	4.49	0.999	1.36e-10	NA	0.584	0.149	0.818	0.541	0.149	4.63	0.999	8.39e-10	NA
HCC38	BX-912	2	72	sigmoid	sigmoid	HCC38 BX-912 0 2 72	8	2.186	0.583	-0.229	0.251	0.648	-0.233	3.62	0.999	9.58e-10	NA	0.602	0.124	0.807	0.559	0.123	3.78	0.998	1.03e-08	NA
HCC38	BX-912	3	72	sigmoid	sigmoid	HCC38 BX-912 0 3 72	8	1.454	0.422	-0.428	0.365	0.478	-0.433	5.0	0.993	4.02e-07	NA	0.496	0.162	0.778	0.46	0.159	5.0	0.989	1.24e-06	NA
HCC38	Dactolisib	1	72	sigmoid	sigmoid	HCC38 dactolisib 0 1 72	8	1.821	0.0109	-0.0403	0.672	0.0104	0.0212	0.892	0.985	3.44e-06	NA	0.0194	0.263	0.492	0.00757	0.301	0.975	0.988	1.65e-06	NA
HCC38	Dactolisib	2	72	sigmoid	sigmoid	HCC38 dactolisib 0 2 72	8	2.120	0.0118	-0.0557	0.668	0.0118	-0.00134	0.785	0.98	7.61e-06	NA	0.0145	0.204	0.447	0.00701	0.245	0.927	0.988	1.88e-06	NA
HCC38	Dactolisib	3	72	sigmoid	sigmoid	HCC38 dactolisib 0 3 72	8	1.468	0.0082	-0.197	0.778	0.0127	-0.181	0.711	0.993	3.98e-07	NA	0.0268	0.262	0.497	0.00923	0.277	0.757	0.994	2.62e-07	NA
HCC38	Everolimus	1	72	sigmoid	flat	HCC38 everolimus 0 1 72	8	1.703	11.8	0.54	0.428	0.000126	0.341	0.1	0.688	0.0303	NA	Inf	0.641	0.664	0.0	0.641	0.01	0.571	0.0788	0.665
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
HCC38	Everolimus	3	72	sigmoid	sigmoid	HCC38 everolimus 0 3 72	8	1.437	5.11	0.511	0.429	0.000567	0.299	0.1	0.934	0.000284	NA	573000000.0	0.668	0.707	0.000349	0.53	0.1	0.932	0.000308	NA
HCC38	CAL-101	1	72	sigmoid	sigmoid	HCC38 idelalisib 0 1 72	8	1.723	Inf	0.92	0.00328	1.18	0.903	1.47	0.768	0.0125	NA	Inf	0.932	0.997	1.16	0.918	1.48	0.763	0.0133	NA
HCC38	CAL-101	2	72	sigmoid	sigmoid	HCC38 idelalisib 0 2 72	8	2.154	Inf	0.881	0.0205	0.901	0.879	3.37	0.892	0.00125	NA	Inf	0.876	0.979	0.891	0.874	3.37	0.887	0.00144	NA
HCC38	CAL-101	3	72	sigmoid	sigmoid	HCC38 idelalisib 0 3 72	8	1.443	Inf	0.851	0.0804	4.08	0.726	0.225	0.706	0.0254	NA	Inf	0.894	0.943	4.27	0.804	0.222	0.707	0.0252	NA
HCC38	KIN001-244	1	72	sigmoid	sigmoid	HCC38 KIN001-244 0 1 72	8	1.751	Inf	0.894	0.0375	4.46	0.77	0.479	0.71	0.0244	NA	Inf	0.909	0.968	4.5	0.802	0.474	0.705	0.0256	NA
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.0	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.0	0.944	0.01	-0.0218	1.0	0.966
HCC38	KIN001-244	3	72	flat	flat	HCC38 KIN001-244 0 3 72	8	1.472	Inf	0.849	0.0658	0.0	0.849	0.01	0.182	0.548	0.929	Inf	0.891	0.952	0.0	0.891	0.01	0.181	0.549	0.948
HCC38	MK2206	1	72	sigmoid	sigmoid	HCC38 MK-2206 0 1 72	8	1.789	19.4	0.698	0.0995	320.0	-0.949	0.38	0.956	8.33e-05	NA	61.8	0.746	0.914	61.8	0.0	0.386	0.951	0.000115	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)